Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies.

Z. Wang, S. Kar, B. I. Carr

Research output: Contribution to journalArticle

Abstract

Cdc25A, a dual specificity protein phosphatase, is well-recognized as a critical regulator for cell cycle progression. We recently found that it also regulates mitogen-activated protein kinase (MAPK) signal transduction pathway. Inhibition of Cdc25A activity by a K vitamin analog Compound 5 (Cpd 5) can induce a strong and prolonged activation of epidermal growth factor receptor (EGFR)-MAPK pathway, which leads to suppression of transcription factors CREB and c-Myc, resulting in decreased expression of Cdc25A and cyclin D1 levels. Our investigations suggest that Cdc25A plays a central role in regulating and linking cell cycle progression and MAPK signal transduction pathways. Several other recently synthesized K vitamin analogs also affect this pathway, including the non-quinone PM20 and fluoro-Cpd 5. Thus, searching for new and efficient small molecules to inhibit Cdc25A activity may provide new means to control cancers of the liver and other sites.

Original languageEnglish
Pages (from-to)863-871
Number of pages9
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume8
Issue number8
Publication statusPublished - Dec 2008

Fingerprint

cdc25 Phosphatases
Phosphoprotein Phosphatases
Liver Neoplasms
Mitogen-Activated Protein Kinases
Vitamin K
Signal Transduction
Cell Cycle
Dual-Specificity Phosphatases
Cyclin D1
Epidermal Growth Factor Receptor
Transcription Factors
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology

Cite this

Cdc25A protein phosphatase : a therapeutic target for liver cancer therapies. / Wang, Z.; Kar, S.; Carr, B. I.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 8, No. 8, 12.2008, p. 863-871.

Research output: Contribution to journalArticle

@article{2c6622ae58b44e62a6ce6adc160afb2a,
title = "Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies.",
abstract = "Cdc25A, a dual specificity protein phosphatase, is well-recognized as a critical regulator for cell cycle progression. We recently found that it also regulates mitogen-activated protein kinase (MAPK) signal transduction pathway. Inhibition of Cdc25A activity by a K vitamin analog Compound 5 (Cpd 5) can induce a strong and prolonged activation of epidermal growth factor receptor (EGFR)-MAPK pathway, which leads to suppression of transcription factors CREB and c-Myc, resulting in decreased expression of Cdc25A and cyclin D1 levels. Our investigations suggest that Cdc25A plays a central role in regulating and linking cell cycle progression and MAPK signal transduction pathways. Several other recently synthesized K vitamin analogs also affect this pathway, including the non-quinone PM20 and fluoro-Cpd 5. Thus, searching for new and efficient small molecules to inhibit Cdc25A activity may provide new means to control cancers of the liver and other sites.",
author = "Z. Wang and S. Kar and Carr, {B. I.}",
year = "2008",
month = "12",
language = "English",
volume = "8",
pages = "863--871",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Cdc25A protein phosphatase

T2 - a therapeutic target for liver cancer therapies.

AU - Wang, Z.

AU - Kar, S.

AU - Carr, B. I.

PY - 2008/12

Y1 - 2008/12

N2 - Cdc25A, a dual specificity protein phosphatase, is well-recognized as a critical regulator for cell cycle progression. We recently found that it also regulates mitogen-activated protein kinase (MAPK) signal transduction pathway. Inhibition of Cdc25A activity by a K vitamin analog Compound 5 (Cpd 5) can induce a strong and prolonged activation of epidermal growth factor receptor (EGFR)-MAPK pathway, which leads to suppression of transcription factors CREB and c-Myc, resulting in decreased expression of Cdc25A and cyclin D1 levels. Our investigations suggest that Cdc25A plays a central role in regulating and linking cell cycle progression and MAPK signal transduction pathways. Several other recently synthesized K vitamin analogs also affect this pathway, including the non-quinone PM20 and fluoro-Cpd 5. Thus, searching for new and efficient small molecules to inhibit Cdc25A activity may provide new means to control cancers of the liver and other sites.

AB - Cdc25A, a dual specificity protein phosphatase, is well-recognized as a critical regulator for cell cycle progression. We recently found that it also regulates mitogen-activated protein kinase (MAPK) signal transduction pathway. Inhibition of Cdc25A activity by a K vitamin analog Compound 5 (Cpd 5) can induce a strong and prolonged activation of epidermal growth factor receptor (EGFR)-MAPK pathway, which leads to suppression of transcription factors CREB and c-Myc, resulting in decreased expression of Cdc25A and cyclin D1 levels. Our investigations suggest that Cdc25A plays a central role in regulating and linking cell cycle progression and MAPK signal transduction pathways. Several other recently synthesized K vitamin analogs also affect this pathway, including the non-quinone PM20 and fluoro-Cpd 5. Thus, searching for new and efficient small molecules to inhibit Cdc25A activity may provide new means to control cancers of the liver and other sites.

UR - http://www.scopus.com/inward/record.url?scp=60549104782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549104782&partnerID=8YFLogxK

M3 - Article

C2 - 19075569

AN - SCOPUS:60549104782

VL - 8

SP - 863

EP - 871

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 8

ER -